MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31.

Income Overview

Net Income
-$26,869K
EPS
-$21.83
Unit: Thousand (K) dollars

Income Statement
2026-03-31
Research and development
22,889
General and administrative
5,020
Total operating expenses
27,909
Loss from operations
-27,909
Interest income
1,125
Interest expense
98
Other income (expense)
13
Total other income
1,040
Net loss
-26,869
Basic EPS
-21.83
Diluted EPS
-21.83
Basic Average Shares
1,230,698
Diluted Average Shares
1,230,698
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

Interest income$1,125K Other income(expense)$13K Net loss-$26,869K Total other income$1,040K Interest expense$98K Loss from operations-$27,909K Total operatingexpenses$27,909K Research and development$22,889K General andadministrative$5,020K

Avalyn Pharma Inc. (AVLN)

Avalyn Pharma Inc. (AVLN)